1.175
0.43%
0.005
Sellas Life Sciences Group Inc stock is traded at $1.175, with a volume of 385.16K.
It is up +0.43% in the last 24 hours and down -6.75% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.17
Open:
$1.17
24h Volume:
385.16K
Relative Volume:
0.73
Market Cap:
$76.23M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-0.7581
EPS:
-1.55
Net Cash Flow:
$-36.91M
1W Performance:
-4.47%
1M Performance:
-6.75%
6M Performance:
-11.65%
1Y Performance:
+22.40%
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
Nov-01-18 | Initiated | Oppenheimer | Outperform |
Apr-02-18 | Initiated | H.C. Wainwright | Buy |
Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewswire
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest - MarketBeat
FDA grants rare pediatric disease designation to SELLAS cancer drug By Investing.com - Investing.com Australia
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S - The Bakersfield Californian
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - StockTitan
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Trading Day Triumph: SELLAS Life Sciences Group Inc (SLS) Ends at 1.19, a -2.46 Surge/Plunge - The Dwinnex
SELLAS extends Times Square lease through 2026 - Investing.com
SELLAS extends Times Square lease through 2026 By Investing.com - Investing.com Australia
What is SELLAS Life Sciences Group Inc (SLS) Stock Return on Shareholders’ Capital? - SETE News
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 0.8% - MarketBeat
Biotech Soars On Material Transfer Agreement - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Lombard Odier Asset Management Europe Ltd Sells 15,000 Shares of StoneCo Ltd. (NASDAQ:STNE) - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Steniel Manufacturing board clears share offering to raise up to P315m - manilastandard.net
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - US Post News
SLM price target lowered to $26 from $29 at Wedbush - TipRanks
Setna iO announces new UK headquarters - AviTrader
Inspire Investing LLC Boosts Stake in Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Australia's Stelar Metals rises on copper, silver find - XM
Quarterly Metrics: Quick and Current Ratios for SELLAS Life Sciences Group Inc (SLS) - The Dwinnex
Investor’s Delight: ENDRA Life Sciences Inc (NDRA) Closes Weak at 0.20, Down -6.77 - The Dwinnex
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
Oman India Investment Fund sells shares worth Rs 75 cr in Senco Gold - The Economic Times
Latest News | Oman India Investment Fund Sells Shares Worth Rs 75 Cr in Senco Gold - LatestLY
Major Stake Changes in Senco Gold: Oman-India Fund Sells, ICICI Prudential Buys - Devdiscourse
Plenham Limited statement: Jason Moseley - Bodyshop Magazine
Sensiva Health names Ben Williamson as Chief Executive Officer - WV News
MASLD Associated with Greater Risk of Serious Bacterial Infection Requiring Hospitalization - MD Magazine
Barrow Hanley Mewhinney & Strauss LLC Grows Position in Standex International Co. (NYSE:SXI) - Defense World
Leonoil Completes Major Stake Acquisition of Sierra Rutile - TipRanks
Benjamin Edwards Inc. Buys 169 Shares of Standex International Co. (NYSE:SXI) - Defense World
2,100 Shares in Silicon Laboratories Inc. (NASDAQ:SLAB) Bought by MQS Management LLC - Defense World
(SMTI) Investment Report - Stock Traders Daily
Victory Capital Management Inc. Purchases 150 Shares of Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Avalon Global Asset Management LLC Raises Holdings in Silicon Laboratories Inc. (NASDAQ:SLAB) - MarketBeat
Granite Investment Partners LLC Increases Stock Holdings in Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Seneca Foods stock soars to 52-week high, hits $64 mark - Investing.com
Sylvania Director Buys Shares, Signals Confidence - TipRanks
American Century Companies Inc. Acquires 72,138 Shares of Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory - Yahoo Finance
Daiwa Securities Group Inc. Purchases Shares of 545 Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Standard BioTools proteomics profiling reveals unique - GlobeNewswire
SIS become club partner - Salford City FC
Sierra Nevada returns 1,880g/t silver at Crystal Peak - Mining.com.au
StoneX Group (NASDAQ:SNEX) Hits New 12-Month High at $84.40 - MarketBeat
Penny Stock Under Rs 30: Company Inks MoU for USD 2 Million Blockchain-Based Tokenization Platform Project – Set to Announce Bonus & Stock Split This Month! - Dalal Street Investment Journal
Sylvania Platinum Limited (LON:SLP) Insider Purchases £11,750 in Stock - MarketBeat
Scancell ‘in a strong position for raising funding’ says Panmure - Proactive Investors USA
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):